{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(4)"],"submitter":["Peng D"],"pubmed_abstract":["<h4>Background</h4>Polymyxins have become an important treatment option for carbapenem-resistant organisms (CRO) infections. However, there is a rare of clinical studies on colistin sulfate. This study sought to investigate the rate of clinical improvement and adverse reactions of colistin sulfate in the treatment of severe infections caused by CRO in critically ill patients and assess the factors associated with 28-day all-cause mortality.<h4>Methods</h4>This multicenter retrospective cohort study included intensive care unit (ICU) patients who received colistin sulfate due to CRO infections during July 2021 and May 2022. The primary endpoint was clinical improvement at end of therapy. Secondary endpoints included adverse reactions bacterial clearance rate and 28-day all-cause mortality.<"],"journal":["Journal of thoracic disease"],"pagination":["1794-1804"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10183486"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of colistin sulfate in the treatment of infections caused by carbapenem-resistant organisms: a multicenter retrospective cohort study."],"pmcid":["PMC10183486"],"pubmed_authors":["Zhang F","Yang J","Shao H","Zhao C","Zhang H","Guo S","Chen C","Fang X","Liu Y","Li Z","Peng D","Qiu S","Niu J","Chen Y","Qin B"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of colistin sulfate in the treatment of infections caused by carbapenem-resistant organisms: a multicenter retrospective cohort study.","description":"<h4>Background</h4>Polymyxins have become an important treatment option for carbapenem-resistant organisms (CRO) infections. However, there is a rare of clinical studies on colistin sulfate. This study sought to investigate the rate of clinical improvement and adverse reactions of colistin sulfate in the treatment of severe infections caused by CRO in critically ill patients and assess the factors associated with 28-day all-cause mortality.<h4>Methods</h4>This multicenter retrospective cohort study included intensive care unit (ICU) patients who received colistin sulfate due to CRO infections during July 2021 and May 2022. The primary endpoint was clinical improvement at end of therapy. Secondary endpoints included adverse reactions bacterial clearance rate and 28-day all-cause mortality.<","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-05T09:11:56.173Z","creation":"2025-04-05T09:11:56.173Z"},"accession":"S-EPMC10183486","cross_references":{"pubmed":["37197520"],"doi":["10.21037/jtd-23-336"]}}